Access the full text.
Sign up today, get DeepDyve free for 14 days.
(2000)
High-dose chemo effective in breast cancer afterall (sic)? Longer follow-up may explain why patients in a Dutch study appear to be doing so well. Hem/Oncol Today 2000;1:8–9
(1999)
High - dose chemotherapy ( HD - CT ) with hematopoietic stem cells ( sic ) transplantation ( HSCT ) for metastatic breast cancer ( MBC ) : Results of the French protocol PEGASE 04 ( abstract )
Ori, G. J., Oldstein, Amela, C. A., Rilley (2000)
CONVENTIONAL-DOSE CHEMOTHERAPY COMPARED WITH HIGH-DOSE CHEMOTHERAPY PLUS AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION FOR METASTATIC BREAST CANCER
(2000)
High-dose chemo effective in breast cancer afterall (sic)? Longer follow-up may explain why patients in a Dutch study appear to be doing so well
(2000)
Randomized phase III study of high-dose chemotherapy with cyclophosphamide, thioTEPA and carboplatin in operable breast cancer with 4 or more axillary lymph nodes (abstract)
(1999)
Results from a randomized adjuvant breast cancer study with high dose chemotherapy with CTCb supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy ( abstract )
(2000)
domized phase III study of high - dose chemotherapy with cyclophosphamide , thioTEPA and carboplatin in operable breast cancer with 4 or more axillary lymph nodes ( abstract )
(2000)
Philadelphia Bone Marrow Transplant Group: Conventional-dose chemotherapy compared with high dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer
Clinical trials remain the standard for introducing new treatments into the medical armamentarium. There is a wealth of information contained in survival curves that are the ultimate outcomes reported in most oncology clinical trials. Survival curves report interesting information about the disease and its response to treatment. Unfortunately, and all too often, the limitations of survival curves are not adequately presented in publications and alternative interpretations for the data are not meticulously delineated by authors. The danger inherent in any publication of survival is that the data are not sufficiently ‘mature’ to support the conclusions that are drawn. This would be of little consequence if medical decisions were not based upon reading the latest publication that is acclaimed to be definitive and settle the question ‘once and for all.’ Better understanding of survival curves and how they shape the future of clinical practice may reduce the dangers of these pitfalls.
Acta Haematologica – Karger
Published: Jul 1, 2001
Keywords: Survival curves; Interpretation of clinical trials; Design of clinical trials
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.